CathLab.com was created by healthcare professionals, for healthcare professionals.

Welcome

CathLab.com recognizes that today’s cardiac and vascular professionals are working in a field that is continually evolving in terms of diagnostic, interventional, therapeutic procedures and patient care. New products and technologies are introduced and adopted every day. As a result, there is a need for a site dedicated solely to the non-physician professional, which provides in-depth coverage on current topics. Our site is designed for cardiac and vascular nurses, technologists, educators, managers, and directors, sharing the latest product insights, news, and education on one website.

News

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

March 17, 2017

“Another trial, this time using self-expanding bioprostheses, has shown that TAVR is noninferior to surgical valve replacement in patients with symptomatic severe aortic stenosis and an intermediate surgical risk.”

Live From Washington: ACC 2017, Day One

March 17, 2017

“The first late-breaking clinical trials of the American College of Cardiology 2017 Scientific Sessions started today with a mix of LDL-lowering drugs and interventional therapy in aortic valve disease.”

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

March 15, 2017

“TAVR has taken on a stronger position relative to surgical aortic valve replacement in a focused update to the valvular heart disease guidelines from the American Heart Association (AHA) and American College of Cardiology (ACC), which last underwent a full revision in 2014.”

To Stent or Not to Stent? iFR vs FFR Late Breakers at ACC 2017 Seek to Shake Up Treatment Decisions

March 14, 2017

“How to know exactly which lesions merit treatment and which can safely be left alone for the time being stands out as one of the most compelling question in interventional cardiology. “